Latest Dendreon Stories
SEATTLE, June 13, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Mitchell H. Gold, M.D., President and Chief Executive Officer received the Ernst & Young Entrepreneur Of The Year(Â®) 2011 Pacific Northwest Award in the Emerging Sciences category. Dr.
VANCOUVER, British Columbia, June 8, 2011 /PRNewswire-Asia/ -- Insiderslab.com caught up the convincing insiders trading today for the following companies: QUALCOMM, OpenTable, Automatic Data Processing, Windstream, Citrix, & Dendreon.
Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it.
VANCOUVER, British Columbia, May 27, 2011 /PRNewswire-Asia/ -- Insiderslab.com filtered out all but the most substantial insider transactions made by insiders.
SEATTLE, May 20, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the following conferences: ThinkEquity Annual Healthcare Conference in New York City, NY on May 25, 2011 at 1:00 p.m.
AUBURNDALE, Mass., May 19, 2011 /PRNewswire/ -- Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S.
SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following PROVENGEÂ® (sipuleucel-T) data presentations taking place at the 2011 American Society of Clinical Oncology annual meeting in Chicago, Illinois.
SEATTLE, May 18, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today announced three abstracts accepted for poster presentation detailing clinical trial plans for PROVENGEÂ® (sipuleucel-T) and the clinical trial of DN24-02 in bladder cancer at the upcoming American Society for Clinical Oncology annual meeting in Chicago, Illinois.
MAYWOOD, N.J., May 16, 2011 /PRNewswire/ -- New Jersey Center for Prostate Cancer & Urology is among the first sites in the nation to treat advanced prostate cancer patients with PROVENGEÂ® (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies.
SEATTLE, May 2, 2011 /PRNewswire/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the first quarter ended March 31, 2011. Revenue for the quarter ended March 31, 2011 was $28.1 million compared to $21,000 for the quarter ended March 31, 2010.
- an ornament or knob in the shape of a flower